Advertisement

Framingham-based HeartWare International Inc. (Nasdaq: HTWR) has released a report showing favorable results from a trial in which its miniaturized circulatory support technology was used as a bridge to heart transplantation for patients with end-stage heart failure.

The company presented the results to the American Heart Association on Sunday, saying that the study of patients with HeartWare’s implanted device, the HeartWare Ventricular Assist System,  showed that “92 percent of the investigational device patients met the per protocol primary endpoint of the trial, which was defined as alive on the originally implanted device, transplanted or explanted for recovery at 180 days.”

SOURCE

Advertisement
Advertisement